Mechanism of action of IFN-β in the treatment of multiple sclerosis: A special reference to CD73 and adenosine

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 641-648

  Airas, Laura ^a,b   Niemelä, Jussi ^b   Yegutkin, Gennady ^b   Jalkanen, Sirpa ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Adenosine; CD73; IFN ; Multiple sclerosis

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE PHOSPHATE; BETA INTERFERON; NEUROPROTECTIVE AGENT;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; AUTOPSY; BRAIN; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; CONFERENCE PAPER; CORRELATION FUNCTION; DEPHOSPHORYLATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MICROVASCULATURE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRECURSOR; SAMPLE; STAINING; SYSTEMIC THERAPY; TISSUE SECTION;

EID: 35748951914     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.067     Document Type: Conference Paper

References (33)

1. HEMMER, B. et al. 2002. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3: 291-301.
2. THE IFNB MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP 1995. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45: 1277-1285.
3. JACOBS, L.D. et al. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39: 285-294.
4. YONG, V.W. 2002. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 59: 802-808.
5. HAFLER, D.A. 2004. Multiple sclerosis. J. Clin. Invest. 113: 788-794.
6. PETTY, M.A. & E.H. Lo. 2002. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog. Neurobiol. 68: 311-323.
7. KRAUS, J. et al. 2004. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann. Neurol. 56: 192-205.
8. LOU, J. et al. 1999. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest. 79: 1015-1025.
9. STUVE, O. et al. 1996. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40: 853-863.
10. PATY, D.W. & D.K. Li. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43: 662-667.
11. AIRAS, L. et al. 2000. CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. J. Immunol. 165: 5411-5417.
12. THOMPSON, L.F. et al. 1989. Antibodies to 5′-nucleotidase (CD73), a glycosylphosphatidylinositol-anchored protein, cause human peripheral blood T cells to proliferate. J. Immunol. 143: 1815-1821.
13. CRONSTEIN, B.N. 1995. A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites. J. Invest. Med. 43: 50-57.
14. LENNON, P.F. et al. 1998. Neutrophil-derived 5′-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J. Exp. Med. 188: 1433-1443.
15. MORABITO, L. et al. 1998. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′- nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 101: 295-300.
16. OHTA, A. & M. SITKOVSKY. 2001. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414: 916-920.
17. RIBEIRO, J.A. et al. 2003. Participation of adenosine receptors in neuroprotection. Drug News Perspect. 16: 80-86.
18. MAYNE, M. et al. 2001. Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann. Neurol. 49: 727-735.
19. RUDOLPHI, K.A. et al. 1992. Adenosine and brain ischemia. Cerebrovasc. Brain Metab. Rev. 4: 346-369.
20. BRAUN, N. et al. 1997. Focal cerebral ischemia enhances glial expression of ecto-5′-nucleotidase. Brain Res. 766: 213-226.
21. LUDWIG, H.C. et al. 1999. Expression of CD 73 (ecto-5′-nucleotidase) in 165 glioblastomas by immunohistochemistry and electronmicroscopic histochemistry. Anticancer Res. 19: 1747-1752.
22. ZIMMERMANN, H. 1996. Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog. Neurobiol. 49: 589-618.
23. VOGEL, M. et al. 1992. Soluble low-Km 5′-nucleotidase from electric-ray (Torpedo marmorata) electric organ and bovine cerebral cortex is derived from the glycosyl- phosphatidylinositol-anchored ectoenzyme by phospholipase C cleavage. Biochem. J. 284(Pt 3): 621-624.
24. TSUTSUI, S. et al. 2004. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J. Neurosci. 24: 1521-1529.
25. JOHNSTON, J.B. et al. 2001. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann. Neurol. 49: 650-658.
26. LINDEN, J. 2001. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol. 41: 775-787.
27. JAFFE, E.A. et al. 1973. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52: 2745-2756.
28. AIRAS, L. et al. 1997. Differential regulation and function of CD73, a glycosylphosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. J. Cell Biol. 136: 421-431.
29. NIEMELA, J. et al. 2004. IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5′- nucleotidase) up-regulation. J. Immunol. 172: 1646-1653.
30. HENTTINEN, T. et al. 2003. Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by ecto-5′-nucleotidase/CD73-dependent mechanism. J. Biol. Chem. 278: 24888-24895.
31. THOMPSON, L.F. et al. 2004. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 200: 1395-1405.
32. ARVILOMMI, A.M. et al. 1997. CD73 mediates lymphocyte binding to vascular endothelium in inflamed human skin. Eur. J. Immunol. 27: 248-254.
33. ZIMMERMANN, H. 1992. 5′-Nucleotidase: molecular structure and functional aspects. Biochem. J. 285(Pt 2): 345-365.